pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 11·3 min read
save

No FDA permission, no problem: New flavored vape policy worries experts

A new FDA policy will let some flavored vapes stay on the market without authorization.

May 11, 2026·read at STAT ↗

Health No FDA permission, no problem: New flavored vape policy worries experts Some products can now stay on market without FDA authorization Manage alerts for this article Email this article Share this article By Sarah ToddMay 11, 2026 Reporter, Commercial Determinants of Health Sarah Todd[email protected]Sarah Todd returned to reporting in January 2025 after being assignment editor at STAT since October 2022. You can reach Sarah on Signal at sarahlizchar.47. The tobacco industry chalked up another win on Friday with a new policy announced by the Food and Drug Administration that gives what one expert called a “get-out-of-jail-free card” to some manufacturers illegally selling e-cigarettes and nicotine pouches.

The FDA has a significant backlog of applications from the makers of vapes and nicotine pouches seeking authorization to sell their products. Some have gone ahead and put their products on sale anyway while awaiting word from the agency. In the new guidance, first reported by the New York Times, the agency said it will not prioritize cracking down on illegal sales under two conditions.Advertisement First, the manufacturers’ applications must have been filed and accepted by the FDA.

Second, in the case of flavored vapes, the manufacturers must have provided what the agency deems sufficient data to evaluate whether the product is “appropriate for the protection of public health” — that is, whether the risks for potential youth uptake are outweighed by the benefits it may offer to adult smokers looking to quit. (Notably, the FDA doesn’t have to actually evaluate the public health data for companies to receive carte blanche — that can happen later.)The guidance is troubling for several reasons, said Mitch Zeller, a former head of the Center for Tobacco Products at the FDA. First, the FDA skipped the process of first issuing a draft and allowing public comments before publishing its final draft.

“It is alarming,” Zeller said, because typically the FDA only goes straight to final guidance if there’s a public health emergency. “The only thing that I can figure out is that this was a desperate attempt by the commissioner to try to save his job,” said Zeller, noting that his comment was purely speculative. President Trump reportedly plans to fire FDA commissioner Marty Makary, though no official announcement has been made.

The agency last week also authorized two fruit-flavored vapes from Los Angeles-based company Glas, reversing a previous decision by Makary, who told STAT he’d been “skeptical” that the devices’ technology would be enough to stop underage people from using them.Advertisement A second concern, Zeller said, is that the FDA is effectively granting a “get-out-of-jail-free card” to companies that charged ahead with their products without authorization, which is “fundamentally unfair to companies that were following the rules and kept their products off of the market.” When companies put their products up for sale without the FDA’s permission — whether for tobacco, drugs, or medical devices — that’s illegal, he said. “It’s a horrible precedent that makes no sense legally.” Meanwhile, the new policy does not address the problem of the many illegal flavored vapes imported from China that make up about 70% of the black market, and which the Trump administration has frequently spoken out against. Implicit in the new guidance is the idea that the FDA will concentrate its enforcement efforts in that area.

STAT’s coverage of chronic health issues is supported by a grant from Bloomberg Philanthropies. Our financial supporters are not involved in any decisions about our journalism. children’s health, FDA, public health, tobacco, vaping Submit a correction requestReprints Sarah Todd Reporter, Commercial Determinants of Health Sarah Todd returned to reporting in January 2025 after being assignment editor at STAT since October 2022.

You can reach Sarah on Signal at sarahlizchar.47. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended The Readout May 11, 2026 STAT Plus: Astellas treatment offers new hope to a devastated rare disease community Pharmalot May 11, 2026 STAT Plus: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more Advertisement Morning Rounds May 11, 2026 The connection between periods and mental health Politics May 11, 2026 STAT Plus: Provider, insurer groups rush to shape No Surprises Act arbitration rules Health May 11, 2026 Animal skin disease confirmed in clusters of European men who have sex with men Subscriber Picks

source

Reporting by STAT.

read at STAT ↗
720 words · retrieved May 11
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTELLASUltragenyx Pharmaceutical Inc.
drugs
nicotine2nicotine ER2Rare Disease
topics
DermatologyPsychiatry & CNSRare Disease

related stories

  • 20h agoNovartis may cut around 130 in Switzerland while relocating biologics productionBioSpace
  • Jul 28Anthony Fauci’s pandemic-era diary entriesSTAT
  • Jul 8Are glucose monitors a good thing for 2-year-olds? Experts look at risks, benefitsSTAT
  • Jul 1FDA says Zyn can market its pouches as safer than cigarettesSTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive